Pharmacyclics | Janssen MEDICAL AFFAIRS
We are pleased to announce the following open ibrutinib trials for patient participation and recruitment. We invite you to view the PDFs below for more information on the landscape of our open and enrolling trials.
Our research expands the possibilities and looks beyond the horizon. We understand the complexity of cancer and are committed to understanding what patients need. This drives us to make positive changes for patients that transform the standard of care.
If you are a member of the media and have questions regarding ibrutinib, please contact Eric Anderson: eanderson@pcyc.com.
To contact Medical Information, please call 1-877-877-3536 or visit the site below.
CMRC-03374 04/21
Brands: https://i.postimg.cc/KcWkGM5j/ASCO-2021-Banner.png
Show Specials
Press Releases